Overview
CRSP market data
Price History
CRSP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.47 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.77 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $44.12 – $78.48 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $4.6K · P/B 2.60 · P/S 1,118.22.
Company news
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool · Jul 22, 2026, 11:00 AM
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?The Motley Fool · Jul 20, 2026, 6:15 PM
Vertex’s Crinetics Deal Balances Growth with Integration RiskInvesting.com · Jul 8, 2026, 3:01 PM
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price TargetBenzinga · Jul 6, 2026, 12:45 PM
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jul 6, 2026, 12:15 PM
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive GrowthGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 2, 2026, 2:30 PM
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jun 15, 2026, 9:15 PM
8-K filing — CRISPR Therapeutics AG (CRSP)SEC EDGAR · Jun 4, 2026, 8:45 PM